1618位股民把上市公司告了，获赔超2.75亿元

Core Viewpoint - The court ruling on the securities fraud case involving Longli Bio has significant implications for investor rights and the responsibilities of intermediary institutions in China’s capital market [1][4]. Group 1: Case Background - Longli Bio, once a prominent biomass energy company, was listed on the Shenzhen Stock Exchange in 2011 and engaged in systematic financial fraud from 2015 to mid-2017, inflating profits to hide operational losses [2]. - The company faced severe financial issues leading to a risk warning in January 2018, and it was officially delisted in July 2020, transitioning to the New Third Board for trading [2]. - The China Securities Regulatory Commission (CSRC) found that Longli Bio's fraudulent activities spanned several years, resulting in a maximum fine of 600,000 yuan for the company and additional penalties for its controlling shareholder and other responsible personnel [2]. Group 2: Legal Proceedings and Compensation - Following the delisting, 1,618 investors initiated a collective lawsuit against Longli Bio for losses incurred due to false statements, with the total claim exceeding 900 million yuan [4]. - The Jinan Intermediate People's Court ruled that Longli Bio must compensate investors for a total of 274 million yuan in investment losses, along with additional legal fees and notification costs [4]. - The controlling shareholder, Cheng Shaobo, is held jointly liable for all debts, while the underwriting institution Guolian Minsheng and the accounting firm Lixin are responsible for 5% and 30% of the compensation, respectively [4]. Group 3: Implications for Investors and Intermediaries - The case highlights the critical role of intermediary institutions in preventing financial fraud, as they are often the first line of defense against such misconduct [5]. - Legal experts suggest that increasing the liability of intermediaries and implementing mandatory insurance for company executives could enhance investor protection [5].